<DOC>
	<DOCNO>NCT02595983</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness revusiran ( ALN-TTRSC ) adults transthyretin-mediated amyloidosis , whose disease continue worsen liver transplantation . Dosing discontinue ; patient followed-up safety .</brief_summary>
	<brief_title>The Study Investigational Drug , Revusiran ( ALN-TTRSC ) , Treatment Transthyretin ( TTR ) -Mediated Amyloidosis Patients Whose Disease Has Continued Worsen Following Liver Transplant</brief_title>
	<detailed_description />
	<mesh_term>Polyneuropathies</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Amyloid Neuropathies</mesh_term>
	<mesh_term>Amyloid Neuropathies , Familial</mesh_term>
	<criteria>Diagnosis FAP ( familial amyloidotic polyneuropathy ) document TTR mutation Received orthotopic liver transplant ≥12 month date inform consent An increase polyneuropathy disability ( PND ) score posttransplant Polyneuropathy Disability score ≤3b New York Heart Association ( NYHA ) classification &gt; 2 Other know cause sensorimotor autonomic neuropathy ( eg , autoimmune disease )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>FAP</keyword>
	<keyword>Familial Amyloidotic Polyneuropathy</keyword>
	<keyword>ATTR Amyloidosis</keyword>
	<keyword>Orthotopic Liver Transplant</keyword>
	<keyword>RNAi therapeutic</keyword>
</DOC>